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ABSTRACT 
The tumor microenvironment plays an important role in glioblastoma, the most malignant 
primary brain tumor in adults. Astrocytes are a major component of the glioblastoma tumor 
microenvironment; therefore, their influence on glioblastoma biology needs to be clarified. 
In this thesis, the role of astrocytes was explored with regard to glioblastoma growth, patient 
survival and their potential as a therapeutic target through a set of in vitro and in vivo studies 
and analyses of clinical samples. 
Co-culture experiments identified astrocytes as enhancers of glioblastoma cell growth in cell 
lines and in a patient-derived culture. Furthermore, orthotopic co-injection of astrocytes with 
glioblastoma cells reduced survival of NOD scid mice, compared to mice that received mono-
injection of glioblastoma cells. A gene signature reflecting glioblastoma-activated astrocytes 
was associated with poor prognosis in two glioblastoma datasets. Through this set of 
experiments, astrocytes were thus shown to enhance glioblastoma growth. 
In a glioblastoma tissue collection, a subset of peritumoral astrocytes co-expressing PDGFRα 
and GFAP was examined for biomarker significance; experiments showed that such 
astrocytes did not carry tumor markers, supporting their non-malignant nature. Inter-case 
variability was observed, both with regard to the presence of such a subset and the general 
astrocyte density. High density in the peritumoral areas of the PDGFRα and GFAP co-
expressing astrocytes, but not total astrocyte density, was identified as an independent poor 
prognostic factor. This observation suggests the presence of differentially functional astrocyte 
subsets in glioblastoma holding clinical relevance. 
A high-throughput screening assay was designed to screen a library of compounds in a novel 
glioblastoma/astrocyte co-culture system. The assay was implemented to identify compounds 
that specifically blocked the astrocyte-driven enhancement of glioblastoma growth. Three 
such compounds were identified and one of them was further validated in an additional cell 
line. Results from the high-throughput screen suggested the crosstalk between glioblastoma 
cells and astrocytes as a potential therapeutic target. 
In conclusion, these studies suggest clinically and biologically relevant roles of astrocytes, as 
validated in patient datasets and peritumoral tissue. Co-culture specific drug response implies 
the crosstalk between malignant cells and astrocytes as a candidate target for novel therapies. 
Further studies will lead to better characterization of the mechanisms behind the 
glioblastoma-astrocyte crosstalk, while the clinical association of the novel PDGFRα+/GFAP+ 
peritumoral astrocyte subset should be further investigated and validated in larger cohorts. 
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1 GLIOBLASTOMA: GENERAL INTRODUCTION 
Gliomas are central nervous system (CNS) tumors that display characteristics of glial cells. 
They are mainly classified as astrocytic, oligodendroglial or ependymal tumors, 
encompassing benign, low-grade and high-grade malignancies. 
In particular, diffuse astrocytic and oligodendroglial tumors range from World Health 
Organization (WHO) grade II to IV. Glioblastoma (GBM) is a grade IV astrocytic 
malignancy that belongs to this category and represents the most common malignant brain 
tumor in adults [1]. 
1.1 EPIDEMIOLOGY 
According to the Swedish Cancer Registry, 1400 people are diagnosed with brain tumor 
every year in Sweden [2]. Among primary CNS tumors, GBMs represent 16% of all cases 
and 56.6% of all gliomas, with a median age at diagnosis of 65 years and incidence 1.6 times 
higher in males compared to females [3]. The prognosis of GBM has remained extremely 
poor during the last decades, with a median survival of 15 months despite intensive treatment 
[4]. Risk factors for GBM are largely investigated; currently, ionizing radiations are the most 
established environmental risk factor for glioma [5]. 
1.2 PATHOGENESIS 
GBMs can be divided into primary (more than 90% of the cases) and secondary. Primary 
GBMs arise de novo, without detectable signs of a preexistent pathology [6]. Secondary 
GBMs are rare and show a better prognosis [7]. They result from the evolution of lower grade 
diffuse or anaplastic astrocytomas (WHO grade II or III), and commonly affect patients of 
younger age (below 45 years). Primary and secondary GBMs cannot practically be 
distinguished based on morphology from a histopathological point of view; nevertheless they 
show genetic differences suggesting differential dependency of driver oncogenes and, 
possibly, sensitivity to novel therapies [6]. Distinct cells of origin are in fact thought to 
develop into primary and secondary GBMs [8]. However, the cell of origin of GBM remains 
largely unknown; it is generally thought that neural stem cells, glial progenitors or more 
differentiated cells such as astrocytes may play this role [9]. 
1.2.1 Genetic landscape of glioblastoma 
GBMs are characterized by great genetic instability at multiple levels, from wide 
chromosomal alterations to focal events. During the last decades, integrated approaches have 
uncovered the complexity of genetic mutations, epigenetic modifications as well as signaling 
pathway alterations that lead to malignant transformation of the cell of origin. 
Classically established genetic alterations of GBMs have been initially described as follows: 
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 Primary GBMs: loss of heterozygosity (LOH) at 10q (70%), EGFR amplification 
(36%), P16/INK4A deletion (31%), and phosphatase and tensin homolog (PTEN) 
mutations (25%); 
 Secondary GBMs: LOH 10q (63%) and TP53 mutations (65%) [10]. 
LOH 10q is a frequent genetic event in both primary and secondary GBM. The tumor 
suppressor PTEN maps to 10q23 and is important in the regulation of cell proliferation, 
apoptosis and tumor invasion. There are cases in which PTEN is mutated even without 
chromosome 10 LOH, which suggest that PTEN is a critical gene in GBM pathogenesis [11]. 
Further efforts have widened the understanding of the genetic landscape of GBM. A 
multitude of genes have been described to be targets of amplification, like EGFR, MET, 
PDGFRA, MDM4, MDM2, CCND2, PIK3CA, MYC, CDK4, CDK6 and AKT3. Other genes 
have been defined as targets of deletion, like CDKN2A/B, CDKN2C, PTEN, PARK2 and RB1 
[12].  
Further analyses revealed mutations in various genes, the most significantly mutated being 
the tumor suppressors TP53 (42%), PTEN (33%), NF1 (21%), RB1 (11%) and PIK3R1 
(10%), and the oncogenes EGFR (18%) and PIK3CA (7%) [13, 14]. Specific patterns of 
mutations emerged, such as the mutual exclusion between NF-κB inhibitor α (NFKBIA) 
heterozygous deletion and EGFR amplification [15]. 
1.2.2 Glioblastoma core pathways 
The understanding of the genetic landscape of GBM allowed an integrated approach that 
uncovered the consistent alteration of three critical signaling pathways in GBM, namely 
inactivation of retinoblastoma (RB) and p53 tumor suppressor pathways and activation of 
RTK/Ras/PI3K pathway [14]. A schematic view of the three pathways is shown in Figure 1. 
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Figure 1: Frequent genetic alterations in three critical signaling pathways in GBM. Reprinted with permission 
from [14]. 
In the TCGA study, dysregulated p53 signaling occurred in 87% of the samples, mostly 
resulting from CDKN2A deletion (49%), MDM2 (14%) and MDM4 (7%) amplification, and 
mutation or deletion of TP53 (35%). RB pathway impairment occurred in 78% of the samples 
and was due to the deletion of members of the CDKN2 family, or amplification of CDK4 
(18%), CDK6 (1%), and CCND2 (2%) and mutation or deletion of RB1 (11%). The 
RTK/Ras/PI3K pathway was found to be activated in 88% of tumors as a result of alterations 
that include mutations or deletions in NF1 and PIK3R1 [12, 14].  
Among the RTKs, EGFR, PDGFRα and MET play a substantial role in GBM. EGFR is 
amplified in 50% of the cases and associated with poor prognosis. About half of these 
amplified cases harbor also EGFRvIII mutation which has been linked to worse prognosis 
when compared to wild-type EGFR [12]. PDGF signaling is activated in glioblastoma mainly 
through PDGFRA amplification (15% of the cases) or upregulation of the ligands. The 
activation of c-Met occurs in about 5% of glioblastomas and especially in samples with 
shorter median survival. It also shows association with activation of EGFR/EGFRvIII [12]. 
TERT promoter mutations are also common in GBM [16]. 
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1.2.3 IDH status in brain tumors 
Data revealing IDH mutations in brain tumors shed light on the nature of primary and 
secondary GBMs [7]. 
There are three IDH isoforms, the cytosolic IDH1 and the mitochondrial IDH2 and IDH3. 
Wild-type IDH1 and IDH2 are enzymes which play a role in the Krebs cycle by converting 
isocitrate to α-ketoglutarate (α-KG), ultimately impacting on cell metabolism through 
production of NADPH [17]. The R132H substitution in IDH1 is the most frequently observed 
mutation. Such a modification in the residue R132 increases α-KG and NADPH bindning to 
the active site of IDH1. Mutations in IDH1/2 lead to depletion of α-KG and accumulation of 
the oncometabolite D-2-hydroxyglutarate (D2HG), a reduced form of α-KG [18-20]. High 
D2HG levels interfere with the action of a number of enzymes that use α-ketoglutarate as co-
factor, including enzymes that have an important role in epigenetic regulation, leading to 
aberration in the differentiation program [18]. Prolyl-hydroxylation of collagen is also 
perturbed by D2HG, leading to defects in collagen maturation [21]. Induction of HIF-1α has 
also been shown to be triggered by mutant IDH [22]. Ultimately, the downstream effects of 
IDH1/2 mutation appear to lead to tumor growth by affecting processes such as metabolism, 
epigenetic modifications, basement membrane function and response to hypoxia [12]. 
However, the role of IDH1 mutation is controversial; different experimental approaches have 
suggested a tumor-suppressive activity [23]. 
IDH1/2 mutations are typical of secondary GBMs. Primary GBMs display mutant IDH1/2 
only in less than 5% of the cases, while more than 80% of secondary GBMs carry mutant 
IDH1/2. Mutations of IDH1/2 have been described as an early gliomagenesis event leading to 
development of low-grade gliomas. This strengthens the hypothesis that secondary GBMs 
derive from the evolution of lower grade gliomas, sharing with them a common progenitor 
cell. Figure 2 summarizes the genetic pathways that lead to primary and secondary GBMs; 
they appear to be distinct biological entities requiring specific therapeutic approaches, also 
suggested by the better prognosis carried by secondary GBMs. IDH1 R132H mutation is 
nowadays used as a marker for the distinction of secondary from primary GBMs [7]. 
Interestingly, IDH1 mutation is strongly associated with the glioma-CpG island methylator 
phenotype (G-CIMP) subgroup of GBM, identified following profiling of alterations in 
promoter DNA methylation [24]. 
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Figure 2: Genetic pathways to primary and secondary glioblastomas. Reprinted with permission from [7]. 
Ongoing efforts counting on more sophisticated technology and inclusion of a higher number 
of tumors are predicted to lead to a more accurate understanding of the molecular 
pathogenesis of GBM. 
1.3 DIAGNOSIS AND CLASSIFICATION 
A primary tool for GBM diagnosis is MRI, while the definitive diagnosis of GBM is based on 
histology. Tissue is collected by stereotactic biopsy or after tumor resection in order to 
perform standard histological staining, such as H&E staining, and additional molecular 
biomarker studies. [25, 26]. As shown in Figure 3, hallmarks of GBM histopathology are 
cellular polymorphism, nuclear atypia, mitotic activity, vascular alteration (thrombosis, 
prominent microvascular proliferation), necrosis and pseudopalisading necrosis. GBMs 
typically exhibit spatial heterogeneity and extreme cellular invasion into surrounding brain 
tissue [27-29]. 
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Figure 3: Pathological and cellular features of GBM. Elevated cellular density, pleomorphism and nuclear atypia 
(A). Cell necrosis and necrotic pseudopalisading (B). Microvascular proliferation and glomeruloid structures (C). 
Adapted with permission from [28, 30]. 
Taking into account the most recent findings, the latest WHO classification of CNS tumors 
has incorporated molecular features. In fact, molecular markers are acquiring increasing 
importance as a support to microscopy in brain tumors, including GBM, allowing an accurate 
diagnosis and giving indications about prognosis and response to treatment [25]. In particular, 
according to the 2016 WHO classification of CNS tumors, IDH mutation is used to classify 
GBMs as follows: 
 Glioblastoma, IDH-wildtype (about 90% of cases, corresponding mostly to primary 
GBM); 
 Glioblastoma, IDH-mutant (about 10% of cases, corresponding mostly to secondary 
GBM); 
 Glioblastoma, NOS (“not otherwise specified”, tumors for which a full IDH 
evaluation cannot be performed) [1]. 
In all gliomas, including GBM, IDH mutation is correlated with better prognosis [31], while 
it does not seem to predict response to therapy [12]. 
A variant of GBM has been added to the classification, within the IDH-wildtype group: the 
epithelioid glioblastoma. It is more common in children and younger adults and often carries 
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BRAF V600E mutation and lacks other IDH-wildtype frequent mutations such as EGFR 
amplification and losses on chromosome 10 [1]. 
The only known predictive marker of response to therapy in GBM is the epigenetic silencing 
of the MGMT gene. It encodes a DNA repair protein that removes the alkyl groups from the 
O6 position of guanine, thus interfering with the mechanism of action of chemotherapeutic 
alkylating agents like temozolomide (TMZ), which is standard of care for GBM [12]. MGMT 
status is hard to reveal in a reproducible way through immunohistochemistry but it can be 
assessed through methylation-specific polymerase chain reaction (MSP) [25]. Patients with 
methylated MGMT promoter display better response to therapy, given the fact that MGMT 
antagonizes the action of TMZ [32]. 
A number of additional biomarkers, including 1p19q deletion, TERT promoter mutation and 
EGFR mutation/amplification may nowadays be tested as clinical routine [33].  
1.4 GLIOBLASTOMA HETEROGENEITY 
GBM has classically been referred to as “multiforme” (from Latin, “of multiple shapes”) 
based on its diverse histological features. Indeed, continuously emerging molecular data did 
not prove researchers wrong: GBMs appear to be “multiforme” even from a molecular point 
of view, displaying both inter- and intra-patient variability. 
1.4.1 Molecular subtypes 
Already before the in-depth efforts aimed at unraveling the GBM genetic landscape, a 
number of high-dimensional studies had highlighted the inter-case genetic differences of 
GBM and correlated that with prognosis [34-36]. Interestingly, these studies provided initial 
evidence that glioblastomas, all morphologically classified by histopathology in the same 
WHO grade IV class, can be better defined using molecular classification with regard to their 
nature, histopathological features and outcome. 
A gene expression study of 200 GBMs was performed with the aim of expanding the 
knowledge about molecular subclasses of this disease [37]. Clustering analyses suggested 4 
groups of GBM, named classical, neural, mesenchymal and proneural. These subgroups show 
defining gene expression patterns linked to different brain cell lineages. The proneural 
subtype has been linked to an oligodendrocytic signature, the classical group to an astrocytic 
signature, the mesenchymal to a cultured astroglial signature and, finally, the neural class 
with both oligodendrocytic and astrocytic signatures together with a strong enrichment of 
neuron specific genes [37].  
The neural subtype signature consists of expression of neuronal markers, such as 
NEFL, GABRA1, SYT1, and SLC12A5 [37]. This subtype has not been defined by exclusive 
gene abnormalities compared to other classes. This observation is nowadays explained by the 
fact that the assignment of tumors to the neural subtype is an artifact deriving from the 
collection and analysis of tumor margins contaminated by normal neural tissue, thus 
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invalidating the significance of this class [38, 39]. The remaining three classes are considered 
to be relevant; they carry distinctive molecular alterations and display clinical relevance. 
Accruing evidence suggests that they may derive from diverse cells of origin or be the result 
of cells in different stages of tumor evolution [9, 40]. 
The classical subtype shows chromosome 10 loss and gain of chromosome 7. Although 
chromosome 7 gain is also seen in other GBM subtypes, specific EGFR amplification, and 
consequent overexpression, or EGFRvIII mutations are highly frequent in the classical 
subtype. This subtype also shows a lack of TP53 mutations. Focal 9p21.3 homozygous 
deletion, targeting CDKN2A, is frequently seen in the classical subtype and occurs in 94% of 
the cases with EGFR amplification. This genetic aberration is almost mutually exclusive with 
alterations in RB1, CDK4, and CCDN2 (other members of the RB pathway). This suggests 
that in EGFR amplified classical GBM the RB pathway is deregulated solely through 
CDKN2A deletion. Members of the Sonic Hedgehog (SHH) and Notch pathways, as well as 
the neural precursor and stem cell marker nestin, are also highly expressed in the classical 
subtype [37]. 
The mesenchymal subtype shows predominant impairment of NF1 through focal deletions of 
a chromosomal region at 17q11.2. Mesenchymal markers (such as CHI3L1 and MET) and 
astrocytic markers (CD44 and MERTK) are highly expressed in this subtype, suggesting 
aftermath of a process sharing similarities with epithelial-to-mesenchymal transition or 
dedifferentiation. The mesenchymal subclass has an overall higher component of necrosis 
and inflammatory infiltrates that can be connected to the high expression of members of the 
tumor necrosis factor super family pathway and NF-κB pathway [37]. NF1 impairment has 
been shown to drive tumor-associated microglia/macrophage (TAM) recruitment in the 
mesenchymal subtypes; TAMs may be at the basis of an NF-κB mediated proneural-to-
mesenchymal transition, observed in proneural patients who display a mesenchymal GBM 
recurrence along with radioresistance [39, 41]. 
The proneural class is defined by alterations in PDGFRA and IDH1. Amplification of 
PDGFRA at 4q12 occurs with or without point mutations in the gene at higher rates 
compared to other classes. Most of the IDH1 mutations were found in this subtype, mainly in 
cases without PDGFRA alteration. Also, TP53 mutations or LOH were described mainly in 
this subtype. Chromosome 7 amplification paired with chromosome 10 loss are events that 
are commonly seen in GBM but displayed less prevalence in this subtype accounting roughly 
for half of the samples analyzed. Oligodendrocytic development genes (PDGFRA, NKX2-2, 
and OLIG2) are highly expressed in this subtype [37]. OLIG2 has been suggested to down-
regulate CDKN1 and thereby contribute to increased proliferation [42]. The proneural 
subtype also displays expression of proneural development genes, such as SOX genes [37]. 
Subtype mosaicism and subtype conversion have been observed in GBM patients. Thus, the 
relationship between subgroups has been explored. Mathematical modeling has suggested 
that chromosome 7 gain and chromosome 10 loss followed by loss of CDKN2A and/or 
mutation in TP53 are early events leading to a tumor with proneural-like characteristics. 
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PDGFA and PTEN are key drivers of further alterations. Subtype-specific mutations arise at a 
later stage [40]. 
Patient outcome and response to intensive treatment has been evaluated in these groups. 
Mesenchymal and classical subgroups seem to benefit more from intensive treatment 
compared to the proneural group. At first, patients with proneural GBM showed a trend of 
longer survival [37]. Interestingly, it was later on demonstrated that the survival advantage of 
the proneural class derived from a subgroup of tumors, the G-CIMP GBMs [24, 37]. This is 
in line with younger age, methylated MGMT and IDH1 mutation displayed by G-CIMP 
glioblastoma patients, and the fact that nearly all secondary GBMs analyzed in the study fell 
in the proneural class. 
1.4.2 A deeper layer of heterogeneity 
The advent of single-cell technologies has allowed in-depth studies designed to analyze the 
complexity of cell populations in a given sample. Techniques such as single-cell RNA 
sequencing can in fact provide data on the transcriptomic profile at the single-cell level [43]. 
Studies exploiting such methodology can help to unravel the complexity of human tissues 
and their pathological counterparts, allowing the identification of cell types and functions at 
higher resolution [44]. Such approaches have also been applied to the brain. 
Recent efforts have described different transcriptomic statuses of malignant cells within the 
same GBM case [45-47]. Different malignant cells in the same GBM specimen showed 
mosaic gene expression of different RTKs, including different EGFR variants. This 
observation has important consequences from a therapeutic point of view, given the fact that 
RTKs are commonly explored therapeutic targets [45]. An unbalanced expression of the 
targeted RTK within the same tumor can invalidate the efficacy of a novel therapeutic 
approach. It is therefore important to further explore intra-tumor variability of GBMs. 
In a recent study comparing the single-cell transcriptome data of malignant cells belonging to 
different GBM specimens, four cellular states were defined to drive GBM malignancy. These 
cellular states resemble neural progenitor cells (NPCs), oligodendrocyte-progenitor cells 
(OPCs), astrocytes and mesenchymal cells. At least two of the cellular states occurred in each 
tumor analyzed in the study, but the majority of the cases contained all four states [46]. 
Different distribution rates of the cellular states within the same tumor seem to recapitulate 
one of the three GBM subtypes (proneural, classical or mesenchymal) as defined by Verhaak 
et al., suggesting that bulk GBM transcriptome sequencing allows subtyping at a lower grade 
of resolution [45, 46]. Malignant cells showed plasticity with regard to transition between 
states, and genetic factors were indicated as responsible for the shaping of state distribution 
within the same tumor. EGFR alterations were associated with higher proportion of astrocyte-
like cells. CDK4 amplification was found to be associated with high frequency of NPC-like 
state and PDGFRA amplification with OPC-like state. Finally, abundance of mesenchymal-
like state is favored by deletions at chromosome 5q and NF1 alterations [46]. 
 18 
1.4.3 Cell of origin 
The identification of the cell of origin of GBM is an area of continuous studies. On one hand, 
studies mentioned in the previous sections suggest that GBMs, given their extensive level of 
heterogeneity, hold their origin in different cell types. This concept is supported by a number 
of observations. In fact, GBMs resemble normal neural and glial cell types with regard to 
morphology and marker expression [9]. In addition, transcriptional profiles of the different 
GBM subtypes resemble that of normal glial cell types [37]. Moreover, different cell types 
such neural stem cells, glial precursor cells, oligodendrocyte precursor cells and astrocytes 
have shown potential of giving rise to gliomas in mouse models [48, 49]; different cells of 
origin have also been associated with a specific GBM subtype, malignancy and response to 
drugs [49-51]. 
On the other hand, other models have suggested that a single cell type of origin may give rise 
to the different linages of GBM cells, representing different stages of tumor evolution [40, 
46]. 
Continued studies aimed at better clarifying the cell of origin of GBM are relevant to improve 
the understanding of the disease and the development of new therapies. 
1.5 CURRENT AND EXPERIMENTAL TREATMENT 
Given the highly infiltrative nature of GBM, which represents the basis for its recurrence, the 
diseased tissue cannot be completely resected. Surgery is therefore not curative, and virtually 
all patients experience recurrence that will eventually lead to death [52]. Surgery alone leads 
to a median patient survival of only 3-6 months [53]. 
After being diagnosed with GBM, patients are subjected to surgical resection and then 
generally follow a protocol of radiation with concomitant and maintenance TMZ [54]. In the 
US, patients can be offered tumor treating fields (TTFields, see §3.2.3, p. 32) together with 
maintenance TMZ, given the fact that this regime has been shown to improve progression-
free survival (PFS) and overall survival (OS) compared to TMZ alone [55]. After recurrence, 
the protocol can vary largely depending on clinical characteristics of the patient; surgery and 
radiotherapy (including gamma-knife radiosurgery) can be considered, whereas patients 
mainly receive TMZ rechallenge and nitrosureas. Bevacizumab is also considered for 
recurrent GBM in the USA, while it is not approved for this use in the European Union [26]. 
Further details about therapeutic approaches are provided in §3 (p. 31). 
Efforts are ongoing to understand the complexity of this disease and identify critical 
pathways that are altered in GBM and may become targets for therapy, hopefully improving 
the outcome [56]. As already mentioned, high inter-tumoral GBM heterogeneity makes tumor 
targeting particularly challenging [45]. GBMs are highly heterogeneous also spatially within 
the same tumor, reflecting their transcriptome heterogeneity. Different regions of the same 
tumor vary with regard to oxygenation, proliferation, infiltration and vascularization [52].  
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Other than MGMT methylation, there is a lack of predictive markers for therapy. Failure of 
new experimental therapeutic approaches has been assigned to the intra-tumor heterogeneity 
that allows multiple resistance mechanisms to manifest. It is thus unlikely that one molecule 
alone will be able to cure GBM, because of the cell-cell genetic background differences and 
resistance mechanisms [52]. As an example, treatment-naïve TMZ-resistant clones have been 
identified using single-cell clonal analysis. These clones further showed different sensitivity 
to a panel of chemotherapeutic molecules [57]. This indicates the need for simultaneous 
pathway inhibition in GBM therapy. 
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2 TUMOR MICROENVIRONMENT IN GLIOBLASTOMA 
The brain tumor microenvironment, composed of different cell types and extracellular matrix, 
has emerged as an interesting study field for a broader understanding of brain tumors and 
improved therapy design. A complicated network of crosstalk between malignant cells and 
the tumor microenvironment remarkably alters several properties of the tumor. The brain 
tumor microenvironment is crucial in both primary tumors such as GBM and metastatic brain 
disease that frequently arises from lung, breast and skin cancer [58]. 
2.1  ROLE OF THE MICROENVIRONMENT IN CANCER 
Cancer is a complex disease. Several efforts in the history of cancer research were aimed at 
understanding the mechanisms through which a normal cell transforms into a malignant cell, 
acquiring capacities that include sustained proliferative signaling, evasion of growth 
suppression mechanisms, resistance to apoptosis, replicative immortality, angiogenesis, and 
activated invasion and metastasis [59]. To address this matter it is necessary to analyze not 
only the malignant cells, but also components of the tumor microenvironment [59]. In fact, a 
number of cell types functionally interact with the malignant cells. Cells of the tumor 
microenvironment can become functionally and phenotypically altered, and regulate 
important aspects of tumor biology, including response to chemotherapy. Notably, these 
interactions between cells of the tumor microenvironment and malignant cells may also 
represent interesting novel therapeutic targets [60]. 
The correct function of the healthy brain is made possible by the interactions between the 
different cell populations. Astrocytes, microglia and oligodendrocytes are the main cell 
populations collectively named “glial cells” of the mature central nervous system, or 
alternatively “neuroglia”. The term “glia” comes from Greek and means “glue”, alluding at 
the connective role of these cells, as opposed to the primary functional role of the neurons 
[61]. This is an old definition and is not complete, given the fact that glial cells play 
meaningful roles in brain physiology and pathology.  
Astrocytes are star-shaped cells with elaborate processes. They support neural signaling by 
regulating the chemical environment and participating in the formation of the blood brain 
barrier [62]. They are connected through gap junctions to each other, and receive signals from 
neurons and can signal back to them [63]. Astrocytes regulate synaptogenesis during brain 
development by secreting factors that include the neuroprotective activity-dependent 
neurotrophic factor (ADNF) [64]. They also play an important role in regulating 
neurotransmitter uptake and ion homeostasis. Astrocytes can basically interact with all CNS 
cells [65]. 
Oligodendrocytes hold as main task the myelination of neuronal axons, making the 
transmission of electric signals at extreme speed possible [62]. In addition, oligodendrocytes 
secrete growth factors that act on the neurons, such as brain-derived neurotrophic factor, NT-
3, insulin-like growth factor-1, and TGF-β [64].  
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Microglial cells are the resident macrophages of the brain that origin from either 
hematopoietic cells or neural precursors. They have scavenging functions as macrophages, 
and also secrete a spectrum of cytokines that play a role during inflammation [62]. Microglia 
and astrocytes are implied in neuroplasticity processes by releasing trophic factors that 
comprise fibroblast growth factor (bFGF) and nerve growth factor (NGF). Additionally, 
astrocytes can up- or down-regulate microglial function by secreting factors such as TGF- β 
or IL-12 [64]. 
The physiological equilibrium between these cell types can drastically change in cancer; the 
following paragraphs will address this issue. In fact, GBMs are rich in components of the 
microenvironment. The malignant cells are immerged in a multitude of cell types such as 
astrocytes, macrophages, microglia, endothelial cells and stem-like cells [66]. A mouse study 
compared stromal cells from healthy brain to those from GBM xenografts, named tumor-
associated glial cells (TAGs). Genes associated with self-renewal and immature cell types 
were upregulated in TAGs, which were also able to promote tumor growth in a co-injection 
in vivo model [67]. 
2.2 TUMOR-ASSOCIATED ASTROCYTES 
The astrocytes represent between 20% and 40% of the glial cells in the brain, depending on 
the region [68]. They are very important in several physiological processes and have been 
described to play roles in primary and secondary brain tumors with regard to tumor 
proliferation, invasion and response to treatment [69]. 
Astrocytes react to damages in CNS with a process called astrogliosis, with the aim of 
repairing the affected tissue. Dysfunctions in astrogliosis can however exert harmful effects. 
Astrogliosis is determined by a spectrum of changes in the astrocytes with regard to 
proliferation, metabolism and cell signaling. Many astrocytes in the healthy brain, but not all, 
express GFAP; following CNS injuries, GFAP is upregulated and basically expressed by all 
reactive astrocytes [70, 71]. The changes that astrocytes undergo during astrogliosis seem to 
be important in glioblastoma and other brain tumors, generally leading to pro-tumorigenic 
effects [72]. GBM xenografted mice show a peak of astrogliosis 3 days after implantation, 
with GFAP upregulation happening in parallel with tumor growth. In these settings, the 
extent of astrogliosis has also been shown to strongly correlate with tumor size [73]. 
Astrocytes thus appear to be a complex cell type, which can turn to tumor-associated 
astrocytes (TAAs) under the influence of a malignancy like GBM [74]. 
By comparing gene expression of TAAs and normal astrocytes in PDGF-driven murine 
gliomas, the MHC Class II pathway was found to be active in the former. This signature was 
also shown to predict survival in human proneural GBMs specifically [75].  
Recent studies, also taking advantage of single-cell technologies, have explored the 
previously poorly understood significance of astrocytes subpopulations [76-78]. This poses 
the basis for studies aimed at understanding the biomarker validity of specific TAA 
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subpopulations. For instance, a subpopulation of pSTAT3
+
 astrocytes in brain metastases was 
associated with shorter patient survival [79]. 
2.2.1 Effects on tumor proliferation 
The effects of the astrocytes on tumor growth have been only marginally explored in the past 
years. It was observed that secretion of TGF-β, IL-6, bFGF, EGF and growth/differentiation 
factor-15 (GDF-15) by the astrocytes may play a role in primary brain tumors and brain 
metastases [69, 74]. Reactive astrocytes of the tumor environment also release CHI3L1, 
driving MAPK signaling and favoring proliferation in GBM cells [80]. Furthermore, GBM-
derived extracellular vesicles have been shown to stimulate the astrocytes to release growth 
factors, which in turn can stimulate GBM growth [81]. 
2.2.2 Effects on tumor invasion 
Collectively, multiple studies have indicated the TAAs as important mediators of brain tumor 
invasion. GBM invasion mostly occurs along blood vessels, also exploiting astrocytic end 
feet [82].  
Astrocytes were described to be capable of modulating levels of the pro-form of matrix 
metalloprotease-2 (MMP-2), and in presence of a GBM cell line they were able of converting 
it to active MMP-2, a proteolytic enzyme implicated in the invasiveness of glioma cells [83]. 
In an in vitro model the astrocytes stimulated GBM invasion through a co-culture dependent 
increase in IL-6 production that leads to MMP-14 and MMP-2 activation in GBM cells [84]. 
In another study, the role of glial-derived neurotrophic factor (GDNF) in glioma progression 
was investigated. Astrocytes secreted GDNF, which acted on GBM cells and stimulated their 
invasiveness in vitro involving ERK and Akt pathways [85]. A mouse study using a GDNF 
co-receptor (expressed by GBM cells) inhibitor on mice injected with tumor cells showed 
development of significantly smaller tumors in the treatment group [85]. 
High expression of receptor activator of NFκB ligand (RANKL) has been shown to correlate 
with enhanced invasion in tumor models and TAA accumulation. Low RANKL-expressing 
GBM cells were engineered to overexpress this factor and subsequently implanted in mice, 
where they showed enhanced invasion. The astrocytes were activated by RANKL through the 
NFκB pathway and secreted a number of factors, including TGF-β, that can stimulate glioma 
cell invasion [86]. Moreover, TAAs enhanced in vitro invasion of glioblastoma stem-like 
cells (GSCs) by chemokine and cytokine secretion [87]. 
Astrocytes also express connexin43 (Cx43), a major gap junction protein. A study compared 
glioma invasion in mice carrying wildtype Cx43 astrocytes or C-terminal truncated Cx43 
mutant astrocytes, showing that abolishment of Cx43 function was sufficient to decrease 
glioma spreading [88]. 
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2.2.3 Effects on tumor sensitivity to treatment 
A number of GBM cell lines have been shown to acquire astrocyte-derived chemo-resistance 
to TMZ [89, 90]. Chemoprotection relies on physical contact between astrocytes and GBM, 
as transwell assays have shown. Cx43 is the major component of gap junctional 
communication in astrocytes. When inhibiting gap junctional communication between 
astrocytes and GBM cells in these experiments, the chemoprotective effect of astrocytes was 
lost. Gene-expression profiling revealed that astrocytes alter drug resistance, anti-apoptosis 
and survival genes in GBM through gap junctional communication [91]. 
GBM cells have also been shown to stimulate conversion of normal astrocytes into reactive 
astrocytes in vitro, enhancing their capability of delivering MGMT mRNA back to GBM cells 
via exosomes. Such a mechanism can convert GBM cells from TMZ-sensitive to TMZ-
resistant and could underlie yet another TAA-driven chemoprotection phenomenon [92]. 
In addition, GSCs displayed a reduction in radiosensitivity when co-cultured with astrocytes, 
together with activation of STAT3. Inhibition of STAT3 has shown potential in enhancing 
GSCs radiosensitivity in vitro and orthotopic xenografts [93]. 
2.2.4 Other tumor-supportive effects 
TAAs have also been shown to support GBM survival in distinct ways. For instance, 
resistance to hypoxia and vascularization are enhanced by TAAs. When they are exposed to 
hypoxic conditions, TAAs secrete CCL20 which binds the CCR6 on GBM cells, ultimately 
leading to activation of NF-κB and HIF-1 and resistance to hypoxia. This observation is 
supported by in vivo data: CCR6-deficient GBM xenografts display in fact slower growth and 
poorer vascularization compared to control [94]. 
Vasculogenic mimicry is a process of vascular-like channel formation that is independent of 
endothelial cells and correlates with prognosis in high-grade gliomas. Astrocytes enhanced 
vasculogenic mimicry in an in vitro model relying on TGF-β1. Galunisertib is a TGF-β1 
inhibitor that was shown to inhibit astrocyte-dependent vasculogenic mimicry and tumor 
growth in mice [95]. 
Tumor necrosis factor receptor superfamily 9 (TNFRSF9) inhibition led to tumor eradication 
and prolonged survival in a glioma animal model [96]. Gliomas displayed a higher expression 
of TNFRSF9 when compared to normal brain tissue, and the main source of this factor was a 
subclass of reactive astrocytes found in perivascular and peritumoural areas. This 
phenomenon was especially prominent in IDH1 mutant gliomas [97]. 
Astrocytes, microglia and tumor cells were shown to interact with each other, ultimately 
mediating activation of the JAK/STAT pathway in the astrocytes and secretion of anti-
inflammatory cytokines including IL-10. This crosstalk ultimately causes reactive astrocytes 
to favor an immunosuppressive environment in GBM [98]. 
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Using an in vitro approach, reactive astrocytes have also been described as a key component 
that leads to a tumor-supportive postsurgery microenvironment, potentiating tumor 
aggressiveness. [99]. 
In summary, several studies have explored diverse and complex ways through which TAAs 
affect processes in GBM such as vascularization, immunoprotection and malignant cell 
survival, apoptosis and invasion [74]. 
2.3 TUMOR-ASSOCIATED MICROGLIA/MACROPHAGES 
The resident macrophages in the brain are called microglia. Together, TAMs represent 
approximately 30% of glioma tissue [100]. The origin of TAMs has been debated and 
controversial until recent studies provided new evidence. Microglia have been shown to 
originate during embryogenesis from primitive myeloid precursors in the yolk sac, following 
different waves of hematopoietic events [101, 102]. Macrophages are bone-marrow-derived 
cells that migrate to the brain in pathological settings [103]. Efforts aimed at clarifying the 
ontogeny of TAMs have suggested that both circulating monocytes and resident microglia 
contribute to the brain tumor TAMs, which keep to some extent memory of their source 
[104]. Furthermore, it was observed in genetically engineered mouse models that microglia-
derived TAMs locate mostly in the peritumoral area and perivascular TAMs are mostly 
monocyte-derived [105].  
The clinical significance of TAM infiltration in gliomas has not been definitely clarified; 
studies exist associating presence of TAMs with better or worse patient survival [106]. This 
also suggests the need for a better characterization of TAM subpopulations that may have 
diverse functions and impact on the biology of different GBM subtypes [107]. Mesenchymal 
GBMs have been described to contain the highest quantity of TAMs compared to classical 
and proneural GBMs. Furthermore, high levels of AIF1 expression (a TAM-specific marker) 
correlated with worse and better survival respectively in proneural and mesenchymal GBMs 
from a TCGA dataset [108].  
Experiments performed in vitro have captured a first degree of polarization of TAMs, 
classifying them into M1 (pro-inflammatory) and M2 phenotypes (anti-inflammatory). For 
both states there are data indicating corresponding mediators that lead to polarization. For 
instance, ligands of toll-like receptor 4 (TLR4) and IFN-γ are usually associated with the 
acquisition of M1 polarization, whereas IL-4, IL-10 and IL-13 are associated with M2 
polarization [109]. This compartmentalized view of TAMs polarization is hard to translate in 
vivo, where the biology of TAMs seems more complicated and plastic [110]. Nevertheless, 
the expression of the M1-polarization marker CD74 has interestingly been associated with 
better prognosis in high-grade glioma patients, compatibly with an anti-tumoral 
immunoenvironment [111]. 
Microglia recruited by GBMs display distinct features compared to functional, pro-
inflammatory microglia seen in non-tumoral diseases [66]. A number of factors released by 
GBM cells have been reported to be chemo-attractants for TAMs, such as monocyte 
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chemotactic protein-3 (MCP-3) [112], colony-stimulating factor 1 (CSF-1) [113], 
granulocyte-macrophage colony stimulatory factor (GM-CSF) [114] and EGF [115]. The 
most important factors appear to be CCL2 and CX3CL1 [106]. In general, all these factors 
induce an M2-polarization of the TAMs [116]. In GBM experimental models, malignant cells 
produce Ccl2 which attracts macrophages, and the inhibition of Ccl2 and its receptor Ccr2 
prolongs mouse survival [117]. 
A study from 2002 showed for the first time that microglia could stimulate glioma invasion 
using a Boyden chamber. When further stimulated with GM-CSF or LPS (known to activate 
microglia), they enhanced glioma cell motility to a higher extent [118]. This finding was 
recapitulated in an experiment using mouse microglia-depleted brain slices, and the 
stimulation of glioma invasion was attributed to an increase in the activity of MMP-2 [119]. 
Glioma cells, which themselves release pro-MMP-2, also produce factors that stimulate 
microglia to release membrane type 1 metalloprotease (MT1-MMP) which is responsible for 
the conversion of the pro-enzyme to active MMP-2 [120]. Also the CX3CL1/CX3CR1 
pathway activation has been connected to metalloproteinase activity enhancement; 
furthermore, polymorphisms of the allele CX3CR1 (upregulated in microglia in the context 
of glioma) have been associated with prognosis in glioma patients. The common CX3CR1 
was described to be a favorable prognostic factor in glioblastoma, associated with less 
microglia infiltration [121, 122]. 
It was also shown in a mouse model that microglia depletion led to a 80% reduction in 
glioma mass, while at the same time another study on the same model demonstrated that 
macrophage depletion had the opposite effect, a 33% increase in glioma growth, suggesting a 
complex relationship between glioma and TAMs [120, 123]. 
Colony stimulating factor-1 (CSF-1) is important for macrophage differentiation and 
survival. In another mouse model, a CSF-1R inhibitor was used with the intent of achieving a 
reduction in TAMs and thus a better survival. This study showed that glioma growth and 
progression were blocked using a CSF-1R inhibitor, but the TAMs were still present in the 
tumor. Further analyses showed that these TAMs had been re-educated, leading to a 
reduction in the proportion of M2-polarized macrophages [113], that have been described in 
many tumors as pro-tumorigenic [124]. It was subsequently shown that tumors recur in 50% 
of the mice after continuous CSF-1R inhibition. The mechanism behind the resistance is 
microenvironment-driven. In fact, transplantation of resistant tumors in naïve hosts 
reestablished sensitivity to CSF-1R inhibition. Macrophages were shown to secrete insulin-
like growth factor-1 (IGF-1) thus activating IGF-1 receptor (IGF-1R) on tumor cells that 
responded with activation of phosphatidylinositol 3-kinase (PI3K) pathway [125]. 
In TAMs isolated from mice injected with GBM cells, genes coding for osteoactivin and the 
secreted form of osteopontin were found to be highly expressed compared to control cells. 
The two genes have shown correlation with poor survival in human GBM following patient 
dataset analysis [126]. TAM-derived osteopontin has also shown to lead to suppression of 
glioma growth [127] and reduction in apoptosis [128], depending on experimental settings. 
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The mechanisms that lead to TAM reprogramming and their precise role in gliomas are still 
to be clearly defined. Many studies have shown pro-proliferative effects of TAMs, together 
with capability of disrupting the extracellular matrix (ECM) and promoting glioma invasion, 
while others proposed alternative effects on malignant cells; the actual proportion of 
microglia and macrophage in the glioma/GBM is also still controversial [106]. This likely 
reflects the plasticity and heterogeneity of these cells and a complicated relationship with 
malignant cells, together with lack of a comprehensive view on different TAMs 
subpopulations and functions. Single-cell RNA sequencing strategies are a possible tool to 
further clarify the role of TAMs in brain tumors [129]. 
2.4 BRAIN TUMOR VASCULATURE 
GBM growth, progression, invasiveness and resistance to treatment are also strongly 
dependent on tumor-mediated alterations of the brain vasculature. Neurons, astrocytes, 
endothelial cells, pericytes and ECM components regulate blood supply in the healthy brain 
[130]. A distinct feature of the brain vasculature is the blood-brain barrier (BBB), an interface 
structure where endothelial cells and astrocytes play a major role in regulating the exchanges 
between peripheral circulation and CNS. In pathological conditions such as GBM, the 
disruption of the BBB leads to serious consequences for the CNS [131]. For instance, brain-
tumor-related edema, characterized by water accumulation in the brain with subsequent 
increase in intracranial pressure, is one of the primary causes of death in glioma patients 
[130]. 
GBMs are among the most angiogenic and vascularized tumors. The structure of the 
vasculature in glioblastoma is altered if compared to the healthy brain [132]. Areas of 
angiogenesis are characterized by microvascular proliferation (MVP), where endothelial 
cells, pericytes and smooth muscle cells undergo hyperplasia. MVP has also been associated 
with increased malignancy [66]. The vascular architecture has been shown to be the niche for 
neural stem cells (NSCs) in the healthy brain [133] but also to play a role in brain tumors in 
hosting brain tumor stem cell (BTSCs) [66]. 
Endothelial cells are involved in brain tumor progression through the regulation of oxygen 
and nutrient delivery and the secretion of factors that act on the BTSCs attracting them, 
maintaining them in a stem cell-like state, and stimulating their tumorigenicity [66, 134]. 
Nitric oxide and Notch signaling are thought to be implicated in this process [66]. The 
perivascular niche (PVN) therefore assumes an important role in GBM biology. Pericytes 
have been described to play an essential role in increasing tumor vascular permeability and to 
be implicated in tumor progression, especially NG2-expressing pericytes [66]. HIF-1α has 
also been shown to recruit bone marrow-derived endothelial and pericyte progenitors and 
promote neovascularization in glioblastoma [135]. 
Around the vasculature there are also reactive astrocytes that play an important role in tumor 
progression [66]. Astrocytes residing in the PVN produce SHH which affects BTSC self-
renewal and growth and is correlated with glioma grade [136]. The Gli signaling, effector of 
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the SHH pathway, is also thought to be an important driver of neural stem/progenitor cell 
hyperproliferation and subsequent brain tumor initiation [137, 138]. 
In the initial phase of vascular remodeling, tumor cells organize themselves in close contact 
with existing vessels and start destroying them in a process defined “vessel co-option” [130]. 
Subsequently, endothelial cells actively direct angiogenesis, which is the most common 
mechanism of vessel formation in GBM. Degradation of the extracellular matrix activates the 
endothelial cells that are attracted by the malignant cells expressing pro-angiogenic factors, 
ultimately mediating endothelial cells survival and adhesion. The endothelial cells then 
recruit the pericytes through the expression of PDGF, achieving in this way the formation of 
the basement membrane [66].  
New vessel formation in glioblastoma is mediated by pro-angiogenic growth factors. VEGF 
and SDF-1α are among the most important regulators of angiogenesis, secreted by cells like 
GSCs [139-141]. Hypoxia induces activation of HIF-1α in glioblastoma cells. VEGF is a 
transcriptional target of HIF-1α, and the tumor vasculature express the receptor VEGF 
receptor 2 (VEGFR2) [142, 143]. VEGF also mediates endothelial progenitor cell recruitment 
and proliferation, leading to their differentiation to endothelial cells and de novo vessel 
formation, a process known as vasculogenesis [130]. 
Through analyses of an in vivo model, it was shown that VEGF is also released through a 
mechanism that involves pleiotrophin (PTN), a small angiogenic cytokine. PTN is expressed 
in the brain during development and is found to be upregulated in tumors. By activating 
anaplastic lymphoma receptor tyrosine kinase (ALK) on perivascular cells, it mediates VEGF 
release in close contact to the vasculature, thus supporting vascular abnormalization in GBM 
[144]. 
Another factor that contributes to tumor vessel abnormalization is the C-Type Lectin CD93, 
which activates β1 integrin signaling [145]. In an orthotopic mouse model of GBM, wild-type 
mice showed shorter survival when compared to CD93
-/-
 mice. In the former, CD93 
expression was mainly restricted to the vasculature that was found to be aberrant, with 
malformed vessels that recapitulated the situation of human GBMs [145, 146]. Laminin-411 
(α4β1γ1) has been shown to increase the expression of Notch pathway members in endothelial 
cells and astrocytes, specifically due to the laminin β1 chain. High vascular laminin-411 
expression in human GBM samples has been associated with higher malignancy, recurrence, 
expression of stem cell markers and shorter patient survival; this may be due to a tumor-
microenvironment crosstalk. Furthermore, longer survival and slower tumor growth were 
observed in a CRISPR/Cas9 laminin-411-depleted GBM mouse model [147]. 
The abnormal status of tumor vasculature is a hallmark of GBM and represents a target for 
novel therapies. Furthermore, there are indications for the association between failure of 
antiangiogenic, VEGF-targeted therapy and tumor vessel status, indicating a potential of 
vascular features to be developed to biomarkers for response to anti-angiogenic treatment 
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[132]. MicroRNAs have also been implicated in the alteration of endothelial cells in GBM 
and as potential therapeutic targets [148, 149]. 
Vasculogenic mimicry, mentioned in §2.2.4 (p. 24), is another important mean of tumor 
vascularization, independent of angiogenesis or endothelial cells. This process has been 
associated to worse prognosis and resistance to radiotherapy in gliomas [130, 150].  
An additional mechanism of tumor vessel shaping is the transdifferentiation of GSCs into 
endothelial cells [151] and pericytes [152]. High pericyte coverage has been associated to 
shorter survival in chemotherapy-treated GBM patients. Interestingly, it has been shown in a 
mouse model that targeting GSC-derived pericytes disrupts the blood-tumor barrier while 
leaving the BBB intact, enhancing therapeutic delivery to the tumor [153].  
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3 THERAPY 
3.1 STUPP REGIMEN 
As mentioned in §1.5 (p. 18), the basis for the current GBM therapy is referred to as “Stupp 
regimen”, based on a study from 2005 analyzing two cohorts that received either 
chemotherapy alone or concomitant chemotherapy and TMZ. From the study it emerged that 
the OS was significantly longer in the group that received the combined therapy compared to 
radiotherapy alone (14.6 and 12.1 months, respectively) [54].  
MGMT methylation status has been demonstrated to correlate with response to therapy. 
Patients with MGMT methylation benefit from combined therapy more than patients with 
unmethylated MGMT (respective median OS: 21.7 and 12.7 months). However, due to a lack 
of better alternatives, combined therapy is still given to both groups of patients [32]. 
3.2 NOVEL THERAPEUTIC APPROACHES 
Given the dismal prognosis of GBM, a constant investigation of novel therapeutic approaches 
has been performed during the last decades. On one hand, a few trials have addressed the 
improvement of surgical intervention (e.g. use of fluorescent dyes like 5-ALA to visualize 
tumor margins during operation), radiotherapy (e.g. gamma-knife radiosurgery) protocols and 
imaging techniques [154, 155]. The major trend has been the evaluation of systemic 
therapies; the following sections will focus on the development of such novel 
pharmacological tools for the treatment of GBM. Among the hundreds of GBM clinical trials 
present on ClinicalTrials.gov, the majority involve the use of either small molecules or 
biological products, and the most promising approaches so far seem to be immunotherapy 
and TTFields (described in §3.2.3, p. 32) [156].  
3.2.1 Angiogenesis targeting studies 
As explained in §2.4 (p. 27), brain tumors are highly vascularized and display abnormal 
vessels with altered permeability. They express high levels of vascular endothelial growth 
factor A (VEGFA) that is responsible for increased angiogenesis and vessel leakiness. The 
levels of VEGFA in brain tumors are increased by hypoxia and acidosis, and cells of the 
tumor microenvironment are also a source of VEGFA [157]. Antiangiogenic therapy has thus 
been explored in GBM. 
Bevacizumab was developed in 1993. It is a humanized variant of an anti-VEGF antibody 
that was able to suppress tumor growth in vivo [158]. Two big double-blinded randomized 
phase III studies have looked at the outcome of newly diagnosed GBM patients treated with 
bevacizumab, thus targeting angiogenesis. Both studies showed similar improvements of 
PFS, but failed to demonstrate increased OS [159, 160]. A retrospective study of one of the 
bevacizumab trials aimed at evaluating the association between GBM molecular subgroups 
and benefit from bevacizumab treatment. The study has reported an improved OS for patients 
of the IDH1 wild-type proneural patients [161]. Even if first-line treatment of GBM with 
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bevacizumab did not lead to positive results, this drug has been approved by FDA for the 
treatment of recurrent GBM in the US. Two clinical trials have in fact demonstrated that 
patients with recurrent GBM benefit from this second-line treatment based on response rate 
assessment [162]. 
Other studies have explored different angiogenesis-targeting approaches in GBM. A 
randomized, open-label phase III study explored the efficacy of cilengitide in newly 
diagnosed glioblastoma [163]. Cilengitide is an anti-angiogenic drug developed in the 90s 
that targets the integrins αvβ3 and αvβ5 [164] which are overexpressed on tumor cells and 
vasculature and were indicated as mediators of tumor-microenvironment crosstalk [163]. This 
study also failed to prove increased OS in the cilengitide group [163]. 
3.2.2 Imipridones 
ONC201 is the first-in-class of a new family of drugs named imipridones. It antagonizes 
members of the dopamine receptors family D2, particularly the dopamine receptor D2 
(DRD2), ultimately inactivating Akt and ERK with anti-proliferative and pro-apoptotic 
effects. The drug has been described to affect tumor cells but not normal cells and to be 
relevant for different types of cancer [165]. 
ONC201 has shown promising results during a phase I clinical trial for GBM which 
highlighted a durable response in a secondary GBM patient carrying the H3 K27M mutation 
[166]. H3 K27M mutant gliomas exhibit an increased DRD2 expression [167]. Mutation in 
H3 K27M is a hallmark of diffuse midline gliomas in children and young adults. Clinical 
trials are evaluating the efficacy of ONC201 in high-grade gliomas, including glioblastoma 
and diffuse midline glioma, H3 K27M mutant or wildtype [166, 168]. 
3.2.3 Tumor treating fields 
Preclinical data has shown that low-intensity, intermediate-frequency (200 kHz) alternating 
electric fields interfere with the mitotic process [169]. These electric fields are called 
TTFields and have been studied as therapeutic approach in a phase III clinical trial comparing 
chemotherapy-free and TTFields treated patients with chemotherapy active patients, showing 
increased quality of life but failing to demonstrate increased OS in the intent-to-treat group 
[170]. After demonstrating the existence of synergy between TTFields and chemotherapy 
[171], a new phase III study was designed to compare chemoradiotherapy followed by 
maintenance treatment consisting of TTFields either with or without TMZ. This study has 
demonstrated a median survival of 20.5 months in the combined TTFields and TMZ group, 
significantly higher than the group that received TMZ alone, of which the median survival 
was 15.6 months [172]. As mentioned in §1.5 (p. 18), only GBM patients in the US can 
currently receive TTField treatment. 
3.2.4 Immunotherapy 
Another field of cancer treatment is immunotherapy, which consists of a number of 
techniques aimed at eliminating malignant cells by exploiting the host’s immune system. It 
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can be divided into active and passive cancer immunotherapy. Active immunotherapy aims at 
directly stimulating the host’s immune system through the infusion of tumor associated 
antigens, for example. Passive immunotherapy mainly uses antibodies directed against tumor 
associated antigens or ex vivo cultured immune cells that are delivered to the patient [173]. 
During the last years, several approaches have been tried with the intent of targeting putative 
tumor associated antigens (as EGFRvIII, IDH1, and even multipeptide vaccines). Other 
approaches used dendritic cells loaded with tumor lysate, tumor peptide, mRNA or glioma 
stem cells. The studies suggest a need for optimization of the protocol with regard to 
parameters such as timing and combination with alternative therapies, together with choosing 
the appropriate biological target. Nevertheless, there is a number of studies that are currently 
active and recruiting patients, mainly in phase I and II [173]. 
3.2.4.1 Personalized immunotherapeutic vaccine 
A completed phase I trial has shown promising results in patients that received a personalized 
immunotherapeutic vaccine where standard of care had failed. These patients were treated 
with Gliovac™, a vaccine preparation composed of autologous (derived from the same 
patient) and allogenic (derived from other patients) antigens, administered together with GM-
CSF. The 6-month survival in the patients that received Gliovac™ was 100%, compared to 
33% in the control group. A phase II study (NCT01903330) is ongoing given the initial 
promising findings on the efficacy of this approach [174]. 
3.2.4.2 EGFR-directed immunotherapy 
Rindopepimut is a vaccine composed of a peptide directed against EGFRvIII linked to 
keyhole limpet haemocyanin (an immunogenic metalloprotein). A phase III trial has failed 
showing increased patient OS and the study was terminated [175]. Other approaches targeting 
EGFR with immunotherapy are under study, such as the use of ABT-414, an antibody-drug 
conjugate targeting EGFR and delivering the antimitotic mafodotin (monomethyl auristatin F, 
a potent antimicrotubule agent) in recurrent GBM patients. The phase I study has highlighted 
a 6-month OS rate of 72.5%, together with some expected ocular toxicities, although the 
therapeutic agent had shown to target mainly the tumor and not healthy tissue [176]. This has 
led to the completion of phase II trials where a better long term OS was observed [177]. 
Unfortunately, the phase III study of ABT-414 did not meet OS primary endpoint and was 
terminated [178]. Failure of such approaches may be explained by the heterogeneity of EGFR 
mutations, which may lead to outgrowth of EGFR mutation-independent clones, and 
mechanisms of resistance that include opportunistic suppression of mutant EGFR upon drug 
treatment [179, 180]. 
3.2.4.3 CAR T cells 
Patient-derived T cells can be engineered to recognize a tumor specific antigen through the 
expression of a chimeric antigen receptor (CAR), obtaining what is defined as CAR T cells. 
CAR T cells have shown relevance in the treatment of liquid tumors and their activity has 
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therefore been explored in solid tumors, including GBM [181, 182]. Studies exist showing 
the potential of CAR T cells in GBM, targeting among others IL-13 receptor alpha 2 (IL-
13Rα2) [183], carbonic anhydrase IX (CAIX) [184] and EGFRvIII [185]. In a phase I clinical 
trial (NCT02208362), IL-13Rα2 targeting led to GBM regression and sustained immune 
response for 7.5 months after treatment with CAR T in one patient with recurrent GBM 
[183]. Further results from the trial have not been posted yet. Anti-CAIX CAR T have shown 
initial promising results in vitro and in a GBM mouse model, displaying a 20% cure rate 
[184]. The phase I trial NCT02209376 analyzed feasibility and safety of anti-EGFRvIII CAR 
T infusion in 10 patients with recurrent GBM. Some of the patients underwent second 
surgery, allowing sampling of the tumor and evaluation of the response to CAR T treatment; 
it was possible to observe an increased T cell trafficking and antigen loss. The median OS 
was around 8 months for the patients object of the study, with one of them staying alive with 
stable disease for 18 months [185]. CAR T cells seem indeed to induce a certain response in 
the patients, but they have to face challenges such as tumor heterogeneity and tumor 
microenvironment-mediated adaptation and escape from the immune response [156]. 
3.2.4.4 Dendritic cell vaccine 
Promising results have been achieved in a phase III study on the dendritic cell vaccine 
DCVax
®
-L in patients with newly diagnosed glioblastoma. The vaccine consists of patient-
derived dendritic cells pulsed with autologous tumor lysate. The intent-to-treat population 
received DCVax
®
-L plus TMZ, and out of 331 patients (median OS of 23.1 months), 100 
extended survivors surprisingly displayed a median OS of 40.5 months. The study has shown 
safety, feasibility and initial efficacy as measured by improved OS and will be continued 
[186]. 
3.2.5 Gene-mediated cytotoxic immunotherapy 
Therapeutic adenoviral delivery of the herpes simplex virus thymidine kinase (TK) has been 
investigated in a Phase II clinical trial for GBM. The patients received local delivery of the 
biological agent to the tumor bed. Subsequently, patients took an oral formulation of the pro-
drug valacyclovir, which is activated by the TK in GBM cells leading to apoptosis. In patients 
with gross total resection, median OS was 25 months in the group receiving aglatimagene 
besadenovec (the adenovirus delivering TK) together with standard of care and 17 months for 
the patients receiving standard of care only [187]. New studies are further evaluating this 
approach in combination with other therapeutics, also led by the fact that the modulation of 
the immune system seems to be a relevant component of this therapeutic approach [156]. 
3.2.6 Macitentan 
A phase I trial focused on targeting astrocytes and endothelial cells in GBM. Studies on in 
vitro models have shown that astrocytes and endothelial cells mediate TMZ chemoprotection 
in GBM, which can be reversed by inhibiting the endothelin signaling. GBM cells express the 
endothelin receptors ETAR and ETBR, while astrocytes and endothelial cells – especially 
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tumor associated endothelial cells – provide the ligand endothelin-1. These observations have 
been translated in vivo in studies providing preclinical validation of the concept [188]. 
Macitentan is an antagonist of ETAR and ETBR. In mice that were given a combination of 
TMZ and Macitentan after implantation of TMZ sensitive or resistant cells, the OS was 
significantly longer than in the single therapy or placebo groups [188]. The receptors are 
expressed in human GBM [189, 190]. The clinical trial (NCT02254954) has unfortunately 
been terminated due to low recruitment; nevertheless, the biology behind this study is still 
interesting. 
3.2.7 Chloroquine 
Chloroquine re-purposing for cancer has been explored following evidence of its anti-
neoplastic potential. Originally designed as an antimalarial medication, chloroquine has 
shown radio/chemo-sensitizing properties [191]. The activity of chloroquine (an autophagy 
inhibitor) has been studied during the last decade as an adjuvant for TMZ therapy, giving 
positive results in mouse models [192] and in patients (14 months of difference in median 
OS) [193]; continued efforts are ongoing to clarify its potential [191]. 
3.3 OUTLOOK ON THERAPY STATE-OF-THE-ART 
In general, the studies mentioned in this section have demonstrated promising potential for 
further development, given the fact that they demonstrated improvement of OS in certain 
cases. Many other studies unfortunately fail translation to the clinics due to unfavorable 
efficacy or safety [194]. When new therapeutic approaches show positive results, they also 
nearly always uncover the need for a deeper understanding of the biology of GBM and its 
microenvironment. In fact, new therapeutic agents have several challenges to face, including 
GBM heterogeneity, BBB penetration, drug resistance, identification of both suitable target 
and population characteristics, and tumor microenvironment mediated therapeutic escape 
[156]. 
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4 STRATEGIES FOR THE IDENTIFICATION OF NEW 
GLIOBLASTOMA TARGETING DRUGS 
Advances in the understanding of cancer biology have uncovered new possibilities for drug 
discovery and development. As discussed before, new therapeutic targets have been 
identified thanks to the insights regarding the alterations that lead to cancer, including GBM. 
Nevertheless, despite a number of compounds that have to some extent displayed efficacy, 
the majority of the compounds fail when brought to clinical trials. 
There are several reasons that can lead to this failure. Some of them include drug resistance, 
alternative mechanisms of escape from the therapeutic effect and the fact that the tumor 
microenvironment complicates the picture of cancer biology, mostly by giving support to 
malignant cells. Eventually, these reasons reflect the fact that cancer is an extremely complex 
disease that is studied using rather simple ex vivo models. When a therapeutic agent is found 
to work on a specific model, subsequent successful validation steps become exponentially 
challenging in mouse models and especially later in human. 
New technologies have made possible the screening of very large numbers of compounds in a 
given model. High-throughput screening (HTS) of compound or biological libraries is a cost 
effective and streamlined way of finding new therapeutics. HTSs can be used to interfere with 
a specific target or phenotype. 
The trend of the last decades in drug discovery has followed a pipeline involving molecular-
target based HTS and hit finding, with subsequent computer-assisted lead identification and 
optimization [195]. This approach benefits from a wide understanding of a certain condition 
object of the study, and it allows screening of small molecules or biologicals such as 
monoclonal antibodies against a given target. Target-based assays investigate a specific 
biological hypothesis relying on one sole target. Novel therapeutic agents that are identified 
in this way can be very strong modulators of the proposed target; at the same time, such a fine 
modulation may not be relevant at all for the disease under investigation [196]. 
Phenotypic assays are a promising substrate for HTS, especially given the fact that they do 
not require prior knowledge of the specific target or mechanism of action. They can help to 
identify novel compounds that directly interfere with a cellular process (e.g. proliferation, 
apoptosis) [196]. Once an interesting compound is identified, the following process of target 
deconvolution is challenging, especially in case of libraries of unknown compounds. There 
are nevertheless assays including cellular thermal shift assay coupled with mass spectrometry 
(MS-CETSA) or in silico analyses that can help to identify the target of a given compound 
[197, 198]. Phenotypic assays have a higher potential of contributing to the development of 
first-in-class drugs than target-based assays [196]. 
There are a number of assays that are suitable for HTS of compounds in biomedical research. 
The activity of several compounds can be evaluated on each hallmark feature of cancer by 
choosing the appropriate assay and the right model [59, 199]. HTS has contributed to the 
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discovery of relevant therapeutics during the past 20 years, leading to a development of the 
methodologies granting enhanced quality of produced data and feasibility [200, 201]. 
Phenotypic HTS assays have also started to contribute to the approval of new therapeutics, 
appearing as a very powerful resource [202]. 
Nevertheless, screening a high number of compounds on a disease-irrelevant model can also 
underlie the risk of long-term failure of drug development. Ordinary cell-line screens with 
validation in xenografts have widely been used to develop drug candidates that unfortunately 
most often have failed to show clinical efficacy. New disease-relevant models are needed in 
order to allow development of new therapeutics by testing them on a system that recapitulates 
the pathophysiological properties of the disease object of investigation [203]. 
Most of the research for new therapeutics in oncology has been pursued on cell lines that 
have been grown for an extended time in culture conditions on plastic substrates. These cell 
lines may become different from the original cancer that they are supposed to represent [203]. 
Such cell lines and derived xenograft models used in drug discovery do change in culture and 
lose the contribution of the original tumor heterogeneity and the tumor microenvironment; 
furthermore, they may display limitation due to misdiagnosis and contamination [204]. 
Alternative approaches to overcome this problem are represented by the use of fresh patient-
derived cultures/xenografts, co-culture systems and organotypic models. 
Patient-derived cultures can better retain the complexity of the original tumor; they can also 
be directly transplanted to immunodeficient mice as patient-derived tumor xenografts and 
transferred from mouse to mouse without being affected from in vitro culture, this way 
representing an interesting model for drug validation following HTS [200, 205]. Following 
HTS of compounds on seven GBM patient derived-cultures, synergy between two test 
compounds was shown to be lethal in a subset of the cultures, suggesting potential for 
precision medicine in GBM [206]. A collection of patient derived human glioblastoma cell 
cultures has been generated containing 48 well characterized cell lines of all molecular 
subtypes [207]. Such a collection has been used to discover novel potential therapeutic targets 
for GBM [208, 209]. In silico approaches may also be integrated with patient-derived 
xenograft studies to identify novel treatment modalities [210]. 
Isolating and focusing on cancer stem cells is also a relevant way of analyzing the activity of 
new drugs, given the fact that they may represent the population of cells that resists therapy 
[204, 211]. In a HTS format, a pyrimidine synthesis inhibitor was found to inhibit 
proliferation, survival, and stemness of glioblastoma-initiating cells in vitro and reduce tumor 
mass in vivo [212]. 
An appropriate way of increasing the likelihood of finding therapeutics that can enhance 
patient survival is to take into strong consideration the role of the tumor microenvironment. 
Many changes in cultured cancer cell lines are due to the missing crosstalk with cells of the 
tumor microenvironment. Co-culture models can be used for HTS of compounds to increase 
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the likelihood of more accurately reproducing key features of a disease in vitro [204]. Co-
culturing GBM cells with cells such as astrocytes or TAMs can uncover features of a given 
compound that would be ignored if it was tested on a monolayer of GBM cells; for instance, a 
pro-tumorigenic crosstalk with cells of the microenvironment can be targeted in such settings, 
and microenvironment-mediated resistance to a given compound can be underscored. 
Cell growth in 3D models has also been shown to better represent the original tumor 
conditions. Furthermore, it has been shown that cells grown in 3D settings may respond 
differently to drugs compared to 2D culture [213]. HTS of compounds in 3D conditions may 
increase the chance of identifying clinically relevant therapeutic agents. 
Spheroids and organotypic models display less compliance to HTS formats, but can represent 
interesting substrates for drug validation; they better reproduce part of the original tumor 
properties [200]. A human GBM organotypic slice culture model can be used for the study of 
GBM in settings that are as close as possible to human, providing a relevant framework for 
drug validation in addition to mouse models [214]. 
A zebrafish GBM model has been proposed as suitable for HTS of drugs. GBM cells can be 
transplanted in an automated and fast way in zebrafish embryos (thousands of embryos per 
hour), avoiding a time-consuming and challenging intracranial transplantation. The resulting 
xenografts have been described to recapitulate human GBM and features of the BBB [215]. 
The stepwise organization of clinical trials in oncology has with time become more elastic, 
given the nature of oncological diseases. Traditionally, phase I studies were mainly meant to 
assess safety and pharmacokinetics of a new therapeutic agent in a limited number of healthy 
volunteers [216]. In oncological clinical trials, phase I studies provide with initial information 
about the efficacy of a new therapeutic target, which is further validated with phase II and III 
studies where the superiority/synergy with standard-of-care treatment is also assessed [217]. 
Choosing the right population that may benefit of a novel therapeutic target is particularly 
important in cancer; this is possible for example by incorporating presence of the specific 
alteration towards which the drug is directed in the patient inclusion criteria. The discovery of 
new clinically relevant biomarkers based on studies of both the malignant cells and 
components of the tumor microenvironment can help to uncover therapeutic effects that 
would be hidden within a non-stratified population of enrolled patients [217]. Properties of 
the complex microenvironment of GBM have shown interesting associations with patient 
survival and response to treatment, as described in §2 (p. 21). The GBM tumor 
microenvironment needs thus to be further investigated for novel biomarkers and taken into 
account in the study of the efficacy of new therapeutics. 
In the GBM drug discovery field, the challenges described so far (tumor heterogeneity, 
therapy resistant glioblastoma-initiating cell, influence of the microenvironment) are 
complicated by the presence of the BBB. A suitable drug for GBM treatment, in fact, should 
be able to cross the BBB and reach the tumor. In vivo experiments following HTS and 
compound optimization can help to understand the potential of a new therapeutics of crossing 
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the BBB. Pathway redundancy and low frequency of common mutations in GBM are also a 
limiting factor for the identification of drug candidates [218]. Given the complexity of GBM, 
it appears necessary to target it from multiple angles, rendering combination therapy 
approaches largely indicated. Because of all the reasons mentioned in this section, it is crucial 
for the discovery and development of drugs in oncology and especially GBM to choose the 
most relevant models for HTS and compound validation.  
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5 PRESENT INVESTIGATION 
5.1 AIMS 
The general aim of this thesis was to investigate the role of astrocytes in GBM. Astrocytes 
were studied with regard to their involvement as regulators of tumor growth and patient 
survival, and subsequently investigated as a therapeutic target. 
Specific aims were: 
 to study the potential of astrocytes as enhancers of GBM growth in vitro and in vivo; 
 to explore the impact of an “astrocyte signature” on patient survival;  
 to examine the prognostic significance of a PDGFRα+/GFAP+ subset of astrocytes in 
a GBM cohort; 
 to identify compounds that are able of interfering with the crosstalk between GBM 
cells and astrocytes by inhibiting the astrocyte-driven tumor growth. 
5.2 RESULTS 
5.2.1 Paper I 
Astrocytes enhance glioblastoma growth 
Cells of the tumor microenvironment play a crucial role in the biology of GBM. The role of 
astrocytes has received only marginal focus until recently. In particular, we have investigated 
the role of astrocytes in GBM growth with in vitro co-culture models and an in vivo co-
injection model. Furthermore, we analyzed the crosstalk between GBM cells and astrocytes 
by evaluating perturbations in gene expression of naïve cells with co-cultured cells. We then 
used such gene-expression alterations to speculate on how GBM-conditioned astrocytes 
affect patient survival. 
We co-cultured GBM cells with astrocytes and subsequently sorted each population out via 
FACS. We compared gene expression of GBM-conditioned astrocytes to that of naïve 
astrocytes, identifying a number of genes (e.g. PLA2R1, ADA, TLR4, ANKRD1) whose 
expression levels are changed upon co-culture with GBM cells. We used this collection of 
differentially expressed genes to assemble an “astrocyte signature” that we then screened 
against GBM gene expression data from a TCGA cohort, detecting significantly shorter 
survival in those patients with a high astrocyte signature score. This observation was 
validated in an additional cohort. The astrocyte signature score was found to be higher in the 
mesenchymal subgroup of GBM and to correlate with unmethylated MGMT promoter. 
Using a format similar to the aforementioned one, we identified deregulated genes in GBM 
after exposure to astrocytes. Periostin (POSTN) and serglycin (SRGN) were found to be 
upregulated in astrocyte-conditioned GBM cells, and associated with the high astrocyte 
signature group of the TCGA cohort. 
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We evaluated GBM growth in the presence or absence of astrocytes. Using commercially 
available GBM cell lines and a patient derived GBM culture, we demonstrated that astrocytes 
enhance GBM growth in vitro. In addition, results were reproduced using a primary astrocyte 
culture. Further analyses suggested specific astrocyte-dependent growth enhancement and 
increased S-phase entry of GBM cells. 
We tested our hypothesis in vivo using a NOD scid mouse model, comparing survival of mice 
that received mono-injection of GBM cells to that of mice that received co-injection of GBM 
cells together with astrocytes. Co-injected mice displayed a shorter survival. Interestingly, 
POSTN and SRGN were found to be upregulated in tumors from such group of mice. This 
supports the hypothesis that astrocytes contribute to increased GBM aggressiveness. 
In summary, this study provides evidence of a previously unrecognized effect of the 
astrocytes on GBM growth using multiple approaches. The study also proposes a gene 
signature reflecting activated status of GBM-associated astrocytes, which are implied as 
enhancers of GBM aggressiveness through correlative analyses of clinical samples. The study 
also presents putative mediators of the GBM-astrocyte crosstalk and a mouse model suitable 
for further investigations. 
5.2.2 Paper II 
Platelet‐derived growth factor receptor α/glial fibrillary acidic protein expressing 
peritumoral astrocytes associate with shorter median overall survival in glioblastoma 
patients 
In the process of GBM growth and invasion, malignant cells crosstalk with cells of the 
microenvironment, including astrocytes. The relationship between the astrocytes and 
malignant cells affects GBM biology in a pro-tumorigenic manner. Astrocytes have been 
described to display heterogeneity in physiological and pathological conditions. PDGF 
signaling is involved in GBM and astrocyte biology. The significance of astrocyte subsets in 
GBM has not been widely explored; in this paper we studied the potential of a PDGFRα+ 
astrocyte subset in the GBM peritumoral area (PTA) by performing analyses of 
immunohistochemically stained tissue. 
By screening a cohort of 45 patients for which PTA was available in the tissue, presence of 
PDGFRα+/GFAP+ astrocytes were encountered in 13 cases. Given the infiltrative nature of 
GBM and potential marker overlapping between malignant cells and astrocytes, experiments 
were performed to support the non-malignant nature of identified PDGFRα+/GFAP+ cells. 
Evaluation of Ki67 status and EGFR, PDGFRA and chromosome 7 copy number variation 
supported the idea that PDGFRα+/GFAP+ astrocyte-like cells in the peritumoral area were 
host cells. 
Total GFAP
+
 astrocyte density was found to vary significantly throughout the cohort. 
Presence of the double positive astrocytes was associated with older age, and not associated 
to other clinico-pathological characteristics (sex, MGMT methylation). Presence of double 
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positive astrocytes was found to be associated with astrocyte density. Interestingly, presence 
of double positive astrocytes, but not total astrocyte density, significantly correlated with 
shorter patient survival. A multi-variable analysis subsequently confirmed the survival 
association, interestingly showing independence from high age. 
This study has thus identified the presence of PDGFRα+/GFAP+ astrocytes in the PTA as a 
candidate biomarker for poorer prognosis in GBM. Further studies on this subset may reveal 
previously unrecognized functions of this astrocyte subset. 
5.2.3 Paper III 
A high-throughput screen to explore the astrocyte-driven enhancement of glioblastoma 
growth as a candidate therapeutic target 
Novel therapeutic approaches are particularly needed in GBM, given the dismal prognosis 
despite intensive therapy and continued attempts to develop new drugs. Lack of focus on the 
contribution of the tumor microenvironment to cancer is among the reasons that may lead to 
failure of the development of a new therapeutic agent. 
Given the role of astrocytes as enhancers of GBM growth, we set up this study to identify 
compounds that interfere with such pro-proliferative activity of the astrocytes. This study is 
also motivated by the need of screening compounds on a relevant model system that 
recapitulates human in vivo settings, instead of solely focusing on the malignant cells. Such 
an approach may increase the clinical translation potential of identified compounds. 
We optimized our phenotypic assay described in Paper I in order to make it suitable for HTS 
of compounds. Using a collection of 1200 known and approved drugs (the Prestwick library), 
we searched for active compounds that were able of interfering with the astrocyte-driven 
enhancement of GBM cell growth. 
Out of 205 compounds found to be active, 17 displayed specific activity in co-culture 
settings. Further validation assays confirmed three of these compounds as specifically 
interfering with the crosstalk between GBM cells and astrocytes. One of these candidate 
compounds was further validated on an additional cell line, where it displayed specific 
activity on the astrocyte-driven enhancement of GBM cell growth, while not affecting the 
autocrine GBM cell growth enhancement. 
Preliminary analyses showed basis for further validation of the identified compounds, 
suggesting the astrocyte-GBM crosstalk as a potential therapeutic target in GBM. 
5.3 CONCLUSIONS AND FUTURE PERSPECTIVES 
GBM is an aggressive disease with an extremely poor prognosis and urgent need for new 
therapeutic approaches. No prominent advances have been made with regard to therapy in the 
last few decades, despite continued studies. Drug discovery and development in GBM is a 
complex field that relies on one hand on the availability of innovative technologies and 
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methodologies and on the other hand on a deep understanding of cancer biology; both 
subjects have developed remarkably during the last couple of decades. 
GBM biology has been profoundly investigated, revealing the complexity of this disease. 
Targeting GBM is challenging given its complicated and heterogeneous genetic landscape 
and the intricate crosstalk between malignant cells and the tumor microenvironment. In paper 
I, we describe tumor-growth enhancing properties of the astrocytes in GBM, together with a 
crosstalk that mediates two-way gene expression changes in both the malignant cells and the 
astrocytes. These observations are recapitulated in vivo, translating in poorer survival of 
astrocyte/GBM cell co-injected mice, and in silico, where an astrocyte signature correlates 
with poorer patient survival in two GBM cohorts. Results from Paper I are supported by those 
in Paper II, where we show that the presence of a subset of PDGFRα+/GFAP+ astrocytes in 
GBM patients’ PTA correlates with poorer patient survival, suggesting biomarker properties 
of this astrocyte subset, and postulating an unidentified function of such an astrocyte subset. 
Our results from Paper I and II are in line with other studies mentioned in this thesis that 
describe a critical role of the tumor microenvironment at multiple levels of GBM biology. 
Paper I and Paper II suggest further studies to improve elucidation of the importance of the 
astrocytes in GBM. The absence of a widely recognized TAA marker represents a challenge 
for the characterization of TAA populations. The astrocyte signature could be analyzed in 
additional cohorts, also with regard to its correlation with response to treatment. In fact, the 
association between high astrocyte score and unmethylated MGMT promoter – a negative 
predictive factor for response to therapy – suggests that astrocyte and malignant cell co-
option may lead to chemotherapeutic resistance. The nature and molecular components of the 
crosstalk between GBM cells and astrocytes should also be clarified with mechanistic studies. 
Such studies may take advantage of the collection of deregulated genes in GBM cells and 
astrocytes following co-culture and the mouse model described in Paper I. The 
PDGFRα+/GFAP+ astrocyte subset should be further analyzed in additional cohorts; the 
definition of its role may benefit of mechanistic studies using mouse models. Additional 
cohort studies may exploit IDH mutated GBMs to discriminate between malignant cells and 
astrocytes, allowing for instance the investigation of the role of this astrocyte subset in GBM 
invasion. In addition, the PDGFRα+/GFAP+ astrocyte subset should be analyzed with regard 
to vascular and immunological properties of GBM. 
The tumor microenvironment is important also as a therapeutic target in cancer, including 
GBM, as studies have suggested. High-throughput technologies have enhanced the 
implementation of drug screenings, reducing their cost and time of realization and providing 
accurate high-content techniques for the investigation of drug activity; despite this, it is 
complicated to setup an appropriate model to perform HTS of compounds that entirely 
recapitulates the human disease. The tumor microenvironment modulates hallmarks of GBM 
and should be taken into account to systematically investigate the activity of novel candidate 
therapeutic agents. In Paper III we performed HTS of compounds on a co-culture model of 
astrocytes and GBM cells with the aim of finding compounds that are able of interfering with 
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the astrocyte-driven enhancement of GBM growth. Three such compounds were identified, 
suggesting further studies to investigate their target and mechanism of action. The chemical 
properties of the identified compounds did not render them immediately suitable for in vivo 
validation. We have in fact analyzed the Prestwick library, composed of known and approved 
drugs. Repurposing existing drugs is particularly challenging in GBM, primarily because they 
should be able to cross the BBB to reach the target. Nevertheless, identified compounds can 
be a tool to unravel the crosstalk between astrocytes and glioblastoma by describing their 
mechanism of action, aided by in vitro and in silico approaches, and possibilities for their 
optimization to work in GBM settings may be further evaluated. In general, results from 
Paper III suggest continued HTS of wider and diverse libraries of compounds on our model 
to discover and develop candidate therapeutic agents for GBM, and the evaluation of their 
synergistic effect with standard therapeutics in GBM. 
Collectively, Papers I-III recognize important roles of the astrocytes in GBM biology: they 
support tumor growth, predict patient survival and can be used as a therapeutic target. Our 
results suggest studies aimed at better understanding the crosstalk between malignant cells 
and astrocytes in GBM and exploiting it to design new therapeutics for this terrible disease.  
 
  47 
6 ACKNOWLEDGEMENTS 
I am extremely grateful to many people that made my experience in Sweden a great and 
positive one, and that shaped my personal and professional development.  
I would like to start by thanking my supervisor Arne Östman for being an excellent guide. 
Your wisdom and passion for science are inspiring and stimulating. I have learnt a lot from 
you during these years; I have admired, among other things, the way you always are able of 
giving relevant inputs and create new directions in projects so naturally. I am also thankful 
for your care about keeping a welcoming atmosphere in the group, and for being an 
understanding and extremely thoughtful person. You have given me the freedom that I 
needed to be able to develop, learn from my own mistakes sometimes, and raise my overall 
awareness. I appreciate your general interest in wellbeing and future perspectives during my 
PhD. I could not ask for better supervision and conditions during these years. 
I also want to thank my co-supervisors Monica Nistér and Daniel Hägerstrand for the 
meetings and support throughout my studies. I have always appreciated your helpfulness and 
the fact you offered alternative point of views and inputs on the projects. Many thanks to my 
co-supervisor Linda Sleire, you were crucial in the initial phase of the project. Thank you for 
guiding me to make my way smoothly in the lab. I take also the chance to acknowledge all 
collaborators for their efforts during my PhD studies. 
Current and past members of the Östman lab and the students who joined throughout the 
years are acknowledged for their support and for adding fun to my time at work! It was nice 
to have you all around. Thank you for being there during my brighter and darker days! 
To all the colleagues that made our floor/department at CCK a warm and fun place to work 
in: thank you, I have lots of good memories there. I am happy some of you are still around at 
Bioclinicum. Thank you for all the fun during pubs, conferences and much more! 
It is impossible to mention you all, but I really mean it: many thanks to all my new and old 
friends. I never feel alone knowing I have you in my life, whether you are close or distant in 
space. I am very happy I made new friends in Sweden; at the same time, I am glad that I can 
still count on my friends in Italy and I love feeling welcome every time I go back. It’s great to 
build new memories with all of you. Special thanks to those friends I could count on every 
single day, you have been and are really important to me. 
Infine, un ringraziamento speciale alla mia famiglia , a cui dedico questa tesi. Vi sono 
grato per il supporto datomi ogni giorno, negli studi e nella vita personale. Quest’esperienza, 
che mi ha portato a numerosi chilometri di distanza, ci ha paradossalmente resi molto più 
uniti. In realtà non ci sono parole per descrivere la mia gratitudine. Mamma e Papà grazie 
per aver sempre creduto in me e per avermi spronato a dare il massimo, continuerò sempre a 
farlo. Ornella, non riesco ad immaginare come sarebbe stato crescere senza di te. Sono 
orgogliosissimo di te e dei traguardi che continui a raggiungere. Grazie per esserci sempre. Vi 
voglio bene. 
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